Hypercalcemia is a condition in which the calcium level in blood augments above normal. It is a result of overactive parathyroid glands. Cancer, hereditary factors, and immobility are some of the reasons of hypercalcemia. Moreover, individuals aged 50 year and above are at a greater risk of overactive parathyroid glands. The effective growth in prevalence of hyperparathyroidism-connected hypercalcemia is projected to propel the hypercalcemia treatment market.
According
to the report analysis, ‘Global Hypercalcemia Market Status (2015-2019) and
Forecast (2020-2024) by Region, Product Type & End-Use’ states
that Bayer Pharma AG, Sun Pharmaceutical Industries, Mylan NV, Pfizer, Amgen, Novartis
AG, Dr.Reddy's Laboratories, Cipla and many more are the foremost market
players which recently working in the global hypercalcemia market more
proficiently for registering the great value of market share, obtaining the
competitive edge, keep maintaining the governing position, generating the
highest percentage of revenue and leading the highest market growth by
analysing the strategies and policies of government as well as contenders,
increasing the features and benefits of hypercalcemia, establishing the several
research and development programs, decreasing the associated prices of such,
delivering the better customer satisfaction, spreading the awareness connected
to the applications and advantages of hypercalcemia, implementing the policies
of profit making and strategies of expansion and improving the qualitative and
quantitative measures of such.
On
the basis of types, the global hypercalcemia market is classified into Bisphosphonates,
Calcitonin, Glucocorticoids, Denosumab, and Calcimimetics. On the basis of
applications, the global hypercalcemia market is categorized into hospitals,
clinics and independent pharmacy and drug stores.
Not
only has this, the effective growth in prevalence of chronic diseases such as
cancer is expected to augment the incidence of hypercalcemia, in turn propelling
the global hypercalcemia market growth in the forecast period. As hypercalcemia
may be caused by cancer and other conditions, its growing prevalence is projected
to drive the market growth.
Furthermore,
the primary concerns raised by these survey respondents that restricted their
capability were subject enrollment, patient recruitment, financial losses owing
to study cancellation, and financial implications from delayed endpoints. Complete,
these issues negatively impacted the clinical trial and drug development
processes around the globe. Hence, the impact of COVID-19 is projected to limit
growth of the global hypercalcemia market over the forecast duration.
Whereas,
the effective growth in research and development activities connected to
hypercalcemia by the key players functioning in the market is expected to propel
growth of the global hypercalcemia market over the forecast duration.
Therefore, it is predicted that during the near period the market of
hypercalcemia will augment more proficiently over the assessed duration.
For More Information, refer to
below link:-
Contact Us: -
Ken Research
Ankur Gupta, Head Marketing & Communications
support@kenresearch.com
+91-9015378249
No comments:
Post a Comment